Satellite Banner
Technology Networks Header
Thursday, August 28, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
New Whitepaper Highlights Impact of NGS Target Enrichment Assay Choice
Tuesday, December 03, 2013
OGT provides insight on NGS enrichment optimization.

Integrated DNA Technologies Launches xGen® Universal Blocking Oligos
Tuesday, November 26, 2013
Enhancing the performance of target capture experiments.

Oversubscribed NGS and aCGH Workshop Now Available Online
Tuesday, November 26, 2013
OGT’s ASHG 2013 workshop highlights the need for comprehensive genomic analysis.

SeqMan NGen and SeqMan Pro Now Available in Illumina’s BaseSpace Apps
Wednesday, November 13, 2013
New Apps make sequence assembly and analysis workflows available to Company’s customers quickly.

Accel-NGS™ PCR-free DNA Library Kit Launched for NGS Systems
Tuesday, November 12, 2013
Swift Biosciences, Inc. announced the launch of the Accel-NGS™ PCR-free DNA Library Kit for Illumina Next Generation Sequencing (NGS) systems.

Illumina Launches TruGenome Undiagnosed Disease Test
Monday, October 28, 2013
A single clinical test provides unbiased analysis of the whole genome for challenging cases.

Integrated DNA Technologies Launches its First Cancer Panel
Friday, October 25, 2013
Fast and accurate screening for mutations identified in acute myeloid lymphoma using the xGen® Acute Myeloid Lymphoma Panel v1.0.

Expand Research Capabilities Using Targeted NGS
Wednesday, October 23, 2013
Join the latest webinar from Integrated DNA Technologies to learn more.

BioDatomics Increases NGS Research Productivity with Launch of 100 Times Faster, More Intuitive Data Analysis Software
Tuesday, October 22, 2013
The new platform addresses the shortcomings found with current data analysis offerings by delivering much higher performance and an intuitive interface.

<< 4 5 6 7 8 9 10 >>
Showing Results 61 - 70 of 200
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv